Molecular Templates, Inc. (MTEM)
Stock Price:
$8.69 USD
-0.17 (-1.92%)
Updated December 2, 4:00 PM EST - Market closed
Key Info
| Market Cap |
434.19M |
| Revenue (ttm) |
21.55M |
| Net Income (ttm) |
-92.35M |
| Shares Out |
49.03M |
| EPS (ttm) |
-2.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$8.69 |
| Previous Close |
$8.86 |
| Change ($) |
-0.17 |
| Change (%) |
-1.92% |
| Day's Open |
8.89 |
| Day's Range |
8.30 - 8.89 |
| Day's Volume |
256,110 |
| 52-Week Range |
8.30 - 18.26 |
More Stats
| Market Cap |
434.19M |
| Enterprise Value |
345.61M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.03M |
| Float |
n/a |
| EPS (basic) |
2.04 |
| EPS (diluted) |
-2.04 |
| FCF / Share |
-1.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.90M |
| Short Ratio |
4.48 |
| Short % of Float |
n/a |
| Beta |
1.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
20.15 |
| PB Ratio |
5.23 |
| Revenue |
21.55M |
| Operating Income |
-91.33M |
| Net Income |
-92.35M |
| Free Cash Flow |
-56.08M |
| Net Cash |
88.58M |
| Net Cash / Share |
1.77 |
| Gross Margin |
-131.12% |
| Operating Margin |
-423.90% |
| Profit Margin |
-428.60% |
| FCF Margin |
-260.29% |
| ROA |
-43.48% |
| ROE |
-134.37% |
| ROIC |
-94.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.83*
(105.18% upside)
Low
13.0
Current: $8.69
High
22.0
Target: 17.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 22.27 | 13.29 | 3.40 | 1.88 | 76.92 | 14.72 | 12.50 | 5.87 | 0.06 | - |
| Revenue Growth | 67.63% | 291.31% | 80.59% | -97.56% | 422.45% | 17.82% | 112.97% | 9362.9% | - | - |
| Gross Profit | 22.27 | 13.29 | 3.40 | 1.88 | 76.92 | 14.72 | 12.50 | 5.87 | 0.06 | - |
| Operating Income | -70.45 | -31.00 | -17.85 | -10.62 | 26.93 | -31.25 | -26.02 | -20.00 | -30.04 | -23.91 |
| Net Income | -69.42 | -30.29 | -23.14 | -11.03 | 43.82 | -21.58 | -28.42 | -71.14 | -25.65 | -18.68 |
| Shares Outstanding | 37.77 | 29.60 | 11.40 | 0.21 | 6.39 | 5.49 | 5.26 | 4.93 | 4.17 | 3.06 |
| Earnings Per Share | 1.86 | 1.02 | 2.11 | -59.04 | 5.94 | -5.39 | -5.39 | -14.41 | -6.16 | -6.16 |
| EPS Growth | 82.35% | -51.66% | - | - | - | - | - | - | - | - |
| Operating Cash Flow | -25.24 | -4.47 | -14.26 | -9.03 | -38.00 | -27.74 | 10.15 | 29.91 | -23.85 | -22.38 |
| Capital Expenditures | -9.65 | -5.72 | -1.10 | -0.10 | -0.11 | -0.22 | -0.16 | -0.48 | -0.53 | -0.11 |
| Free Cash Flow | -34.89 | -10.19 | -15.37 | -9.13 | -38.11 | -27.96 | 9.99 | 29.43 | -24.38 | -22.49 |
| Cash & Equivalents | 125 | 97.96 | 58.91 | 1.72 | 48.68 | 58.60 | 65.67 | 70.85 | 20.29 | 15.17 |
| Total Debt | 14.62 | 3.25 | 3.48 | 12.88 | - | - | - | - | - | - |
| Net Cash / Debt | 110 | 94.70 | 55.43 | -11.16 | 48.68 | 58.60 | 65.67 | 70.85 | 20.29 | 15.17 |
| Assets | 174 | 140 | 90.39 | 3.10 | 53.67 | 68.40 | 104 | 89.52 | 22.44 | 16.20 |
| Liabilities | 71.17 | 39.25 | 13.10 | 17.03 | 12.82 | 92.37 | 128 | 103 | 17.95 | 11.26 |
| Book Value | 103 | 101 | 77.29 | -39.81 | 40.85 | -23.98 | -23.48 | -13.85 | 4.48 | 4.94 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Molecular Templates, Inc. |
| Country |
United States |
| Employees |
228 |
| CEO |
Eric Poma |
Stock Information
| Ticker Symbol |
MTEM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MTEM |
Description
Molecular Templates, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.